Enterome adds experience to validate microbiome-based approach

French privately-held biotech firm Enterome Bioscience has named Jan Fagerberg its new chief medical officer and Catherine Mathis its chief development officer.

The experienced pair join the microbiome-focused company’s management team, which is led by chief executive, Pierre Belichard, who said: “We are pleased that Jan and Catherine are joining us to complement our team.

“We believe their extensive clinical and regulatory experience across biotech and big pharma will be key assets as we prepare to initiate clinical trials with EO2401, an innovative immunotherapy developed using our molecular mimicry approach, for glioblastoma multiforme.